Standard BioTools Provides Update on Sale of Mass Cytometry Business
Summary
Standard BioTools updated investors on the sale of its Mass Cytometry business and replaced the previously announced buyer with Element Biosystems, an acquisition vehicle formed by GMT Venture Partners. The new agreement values the business at $5.5 million in cash at closing, subject to customary adjustments. Standard BioTools said the revised deal improves its net cash position for the pending Treeline merger and preserves continuity for Mass Cytometry customers and staff. The company expects both the Element sale and the Treeline transaction to close by the end of 2026, subject to stockholder approval and other conditions.
AskAI Classifications
Sectors
Life Sciences and Pharmaceutical
Life Sciences Management
Life Sciences Analytics
Functions
No functions detected
Linked Companies
Standard BioTools
$100M to $250M